Phenylketonuria Treatment Market Outlook Analysis
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 18 2026
0mins
Should l Buy BMRN?
Source: Newsfilter
- Market Size Growth: The phenylketonuria treatment market is expected to continue growing by 2034, with the U.S. holding the largest market size, as evidenced by 18,800 diagnosed PKU cases in 2024, indicating strong demand and economic opportunities in this sector.
- Emerging Therapies Development: New therapies such as NGGT002, JNT-517, and Pegvaliase are currently in clinical trials and are anticipated to enter the market in the coming years, significantly improving treatment options for patients and driving market transformation.
- Increased Screening Rates: The expansion of newborn screening programs globally has led to higher early diagnosis rates of PKU, resulting in more patients entering care pathways, thereby enhancing the market's growth potential and meeting rising healthcare demands.
- Regulatory Support: The approvals of PTC Therapeutics' SEPHIENCE and BioMarin's Pegvaliase by the FDA and Japan's Ministry of Health signify an improved regulatory environment, providing favorable conditions for new therapies' market entry and fostering innovation and development in the industry.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BMRN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BMRN
Wall Street analysts forecast BMRN stock price to rise
19 Analyst Rating
14 Buy
5 Hold
0 Sell
Moderate Buy
Current: 60.880
Low
60.00
Averages
87.35
High
120.00
Current: 60.880
Low
60.00
Averages
87.35
High
120.00
About BMRN
BioMarin Pharmaceutical Inc. is a global biotechnology company engaged in the development of genetic discovery into medicines that make an impact on the life of each patient. The Company has eight commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its key clinical programs include Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701. Its late-stage enzyme replacement therapy, INZ-701, is being developed for the treatment of ENPP1 deficiency.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BioMarin Pharmaceutical Outlines Strategic Refresh and Market Outlook
- Strategic Update: BioMarin Pharmaceutical emphasized its strategic refresh at the TD Cowen conference, particularly through the Inozyme deal and the pending Amicus acquisition, aiming to expand enzyme therapy scale across approximately 80 countries, thereby enhancing its competitive position in the rare disease market.
- Revenue Outlook: Despite anticipating a roughly 3% revenue headwind in 2026 due to the removal of ROCTAVIAN and Kuvan revenue declines, BioMarin expects core enzyme and skeletal businesses to grow at mid-to-high single digits, targeting a 40% operating margin by 2026.
- Competitive Dynamics: BioMarin anticipates new FDA-approved competition for Voxzogo; however, management believes that patient switching will be gradual due to its five-year market lead and strong patient adherence, which will help maintain market share.
- Clinical Catalysts: BioMarin is advancing multiple clinical trials, including a Phase 3 study for hypochondroplasia and a pediatric Phase 3 study for BMN 401, which are expected to provide significant growth drivers for the company, particularly in the global rare disease treatment landscape.
See More
FDA Grants Approvals for Multiple New Therapies
- Hernexeos Approval: On February 26, 2026, the FDA granted accelerated approval to Boehringer Ingelheim's Hernexeos as a first-line treatment for adult patients with HER2-mutant advanced non-small cell lung cancer, representing a significant milestone that could improve patient prognosis and reduce the risk of brain metastases for the 2-4% of NSCLC cases affected.
- Yuviwel Launch: Ascendis Pharma secured FDA approval on February 27, 2026, for Yuviwel, the first and only therapy providing continuous systemic exposure to C-type natriuretic peptide (CNP) for children aged 2 and older with achondroplasia, which is expected to enhance treatment adherence compared to daily alternatives.
- Palynziq Indication Expansion: BioMarin received FDA approval on February 27, 2026, to expand Palynziq's indication to include pediatric patients aged 12 and older with phenylketonuria, which is anticipated to further drive sales growth, having generated $433 million in revenue in 2025.
- Sogroya New Indications: Novo Nordisk obtained FDA approval on February 27, 2026, for Sogroya's expanded indications for various growth disorders, offering a once-weekly growth hormone alternative that is expected to improve treatment adherence and alleviate the burden of daily injections for families.
See More
UniQure's Gene Therapy Faces FDA Challenges
- FDA Study Requirement: The U.S. FDA has mandated that UniQure conduct a placebo-controlled trial to validate the efficacy of its gene therapy for Huntington's disease, despite the company's claims that such a trial is unethical due to the need for prolonged general anesthesia.
- Clinical Trial Controversy: An FDA official indicated that UniQure's clinical trial data does not meet approval criteria, suggesting that the company may be aware of its earlier trial failures and has not pursued necessary clinical studies.
- Stock Price Fluctuation: Despite facing challenges from the FDA, UniQure's stock rose over 10% on Thursday, although it has fallen 58% this year, reflecting market concerns regarding the therapy's prospects.
- Regulatory Tensions: The relationship between UniQure and the FDA is increasingly strained, with the agency facing criticism for recent drug application rejections, and UniQure accusing the FDA of reversing its acceptance standards for the company's clinical trial data.
See More
FDA Faces Criticism Amid Innovation Challenges
- Regulatory Standards Controversy: Congressman Jake Auchincloss criticized FDA Commissioner Marty Makary for replacing standards of safety and efficacy with fear and favoritism, undermining patient confidence in new therapies and impacting the market launch of innovative drugs.
- Staffing Losses: The FDA has experienced significant staff reductions in its Center for Drug Evaluation and Research, with oncology review staff dropping from about 100 to below 60, which may lead to approval delays and incomplete response letters.
- Decline in Accelerated Approvals: In 2024, the FDA approved 20 drugs through the accelerated approval process, down from 9 the previous year, indicating a direct impact on drug approval efficiency due to the loss of experienced reviewers.
- New Therapy Approval Pathways: The FDA proposed a new system for approving personalized drugs aimed at rare diseases, intending to provide more flexible approval pathways, but this change has sparked widespread controversy, affecting the agency's core mission.
See More
BioMarin's Drug Approved by FDA for PKU Treatment
- FDA Approval: The U.S. FDA has approved BioMarin's supplemental application for Palynziq (pegvaliase-pqpz), making it the only enzyme substitution therapy approved for managing phenylketonuria (PKU) in adolescents aged 12 and older, marking a significant advancement for the company in the rare disease sector.
- Clinical Study Results: The approval is based on the Phase 3 PEGASUS study, which demonstrated statistically significant reductions in blood phenylalanine levels at Week 72 for individuals on Palynziq compared to those on diet alone, indicating the drug's effectiveness in improving patient health outcomes.
- Market Performance Analysis: BioMarin's stock is currently trading at $59.30, which is 4.5% below its 20-day simple moving average and 8.2% below its 100-day simple moving average, reflecting short-term market weakness, with shares down approximately 19% over the past 12 months.
- Analyst Ratings: Despite the challenging market environment, BioMarin's stock carries a Buy rating with an average price target of $88.80, with recent target increases from analysts like Canaccord Genuity and Bernstein, indicating confidence in the company's future potential.
See More
BioMarin Receives FDA Approval for PALYNZIQ in Pediatric Patients
- FDA Approval: BioMarin Pharmaceutical Inc. announced that its PALYNZIQ (pegvaliase-pqpz) has received approval from the U.S. FDA for use in pediatric patients aged 12 and older with phenylketonuria, marking a significant advancement in treatment options.
- Unique Therapy: PALYNZIQ is the only approved enzyme substitution therapy that effectively reduces blood phenylalanine (Phe) concentrations, helping patients with phenylketonuria improve their health outcomes and overall quality of life.
- European Market Expansion: BioMarin is also seeking approval from the European Medicines Agency to expand PALYNZIQ's indication to adolescents aged 12 and older in the European Union, further broadening its market reach.
- Market Reaction: Although BioMarin's stock rose by 1.01% to $61.73 during regular trading on Friday, it fell by 3.92% to $59.31 in after-hours trading, indicating mixed market reactions to the new approval.
See More
BioMarin Pharmaceutical Outlines Strategic Refresh and Market Outlook
- Strategic Update: BioMarin Pharmaceutical emphasized its strategic refresh at the TD Cowen conference, particularly through the Inozyme deal and the pending Amicus acquisition, aiming to expand enzyme therapy scale across approximately 80 countries, thereby enhancing its competitive position in the rare disease market.
- Revenue Outlook: Despite anticipating a roughly 3% revenue headwind in 2026 due to the removal of ROCTAVIAN and Kuvan revenue declines, BioMarin expects core enzyme and skeletal businesses to grow at mid-to-high single digits, targeting a 40% operating margin by 2026.
- Competitive Dynamics: BioMarin anticipates new FDA-approved competition for Voxzogo; however, management believes that patient switching will be gradual due to its five-year market lead and strong patient adherence, which will help maintain market share.
- Clinical Catalysts: BioMarin is advancing multiple clinical trials, including a Phase 3 study for hypochondroplasia and a pediatric Phase 3 study for BMN 401, which are expected to provide significant growth drivers for the company, particularly in the global rare disease treatment landscape.
See More
FDA Grants Approvals for Multiple New Therapies
- Hernexeos Approval: On February 26, 2026, the FDA granted accelerated approval to Boehringer Ingelheim's Hernexeos as a first-line treatment for adult patients with HER2-mutant advanced non-small cell lung cancer, representing a significant milestone that could improve patient prognosis and reduce the risk of brain metastases for the 2-4% of NSCLC cases affected.
- Yuviwel Launch: Ascendis Pharma secured FDA approval on February 27, 2026, for Yuviwel, the first and only therapy providing continuous systemic exposure to C-type natriuretic peptide (CNP) for children aged 2 and older with achondroplasia, which is expected to enhance treatment adherence compared to daily alternatives.
- Palynziq Indication Expansion: BioMarin received FDA approval on February 27, 2026, to expand Palynziq's indication to include pediatric patients aged 12 and older with phenylketonuria, which is anticipated to further drive sales growth, having generated $433 million in revenue in 2025.
- Sogroya New Indications: Novo Nordisk obtained FDA approval on February 27, 2026, for Sogroya's expanded indications for various growth disorders, offering a once-weekly growth hormone alternative that is expected to improve treatment adherence and alleviate the burden of daily injections for families.
See More
UniQure's Gene Therapy Faces FDA Challenges
- FDA Study Requirement: The U.S. FDA has mandated that UniQure conduct a placebo-controlled trial to validate the efficacy of its gene therapy for Huntington's disease, despite the company's claims that such a trial is unethical due to the need for prolonged general anesthesia.
- Clinical Trial Controversy: An FDA official indicated that UniQure's clinical trial data does not meet approval criteria, suggesting that the company may be aware of its earlier trial failures and has not pursued necessary clinical studies.
- Stock Price Fluctuation: Despite facing challenges from the FDA, UniQure's stock rose over 10% on Thursday, although it has fallen 58% this year, reflecting market concerns regarding the therapy's prospects.
- Regulatory Tensions: The relationship between UniQure and the FDA is increasingly strained, with the agency facing criticism for recent drug application rejections, and UniQure accusing the FDA of reversing its acceptance standards for the company's clinical trial data.
See More
FDA Faces Criticism Amid Innovation Challenges
- Regulatory Standards Controversy: Congressman Jake Auchincloss criticized FDA Commissioner Marty Makary for replacing standards of safety and efficacy with fear and favoritism, undermining patient confidence in new therapies and impacting the market launch of innovative drugs.
- Staffing Losses: The FDA has experienced significant staff reductions in its Center for Drug Evaluation and Research, with oncology review staff dropping from about 100 to below 60, which may lead to approval delays and incomplete response letters.
- Decline in Accelerated Approvals: In 2024, the FDA approved 20 drugs through the accelerated approval process, down from 9 the previous year, indicating a direct impact on drug approval efficiency due to the loss of experienced reviewers.
- New Therapy Approval Pathways: The FDA proposed a new system for approving personalized drugs aimed at rare diseases, intending to provide more flexible approval pathways, but this change has sparked widespread controversy, affecting the agency's core mission.
See More
BioMarin's Drug Approved by FDA for PKU Treatment
- FDA Approval: The U.S. FDA has approved BioMarin's supplemental application for Palynziq (pegvaliase-pqpz), making it the only enzyme substitution therapy approved for managing phenylketonuria (PKU) in adolescents aged 12 and older, marking a significant advancement for the company in the rare disease sector.
- Clinical Study Results: The approval is based on the Phase 3 PEGASUS study, which demonstrated statistically significant reductions in blood phenylalanine levels at Week 72 for individuals on Palynziq compared to those on diet alone, indicating the drug's effectiveness in improving patient health outcomes.
- Market Performance Analysis: BioMarin's stock is currently trading at $59.30, which is 4.5% below its 20-day simple moving average and 8.2% below its 100-day simple moving average, reflecting short-term market weakness, with shares down approximately 19% over the past 12 months.
- Analyst Ratings: Despite the challenging market environment, BioMarin's stock carries a Buy rating with an average price target of $88.80, with recent target increases from analysts like Canaccord Genuity and Bernstein, indicating confidence in the company's future potential.
See More
BioMarin Receives FDA Approval for PALYNZIQ in Pediatric Patients
- FDA Approval: BioMarin Pharmaceutical Inc. announced that its PALYNZIQ (pegvaliase-pqpz) has received approval from the U.S. FDA for use in pediatric patients aged 12 and older with phenylketonuria, marking a significant advancement in treatment options.
- Unique Therapy: PALYNZIQ is the only approved enzyme substitution therapy that effectively reduces blood phenylalanine (Phe) concentrations, helping patients with phenylketonuria improve their health outcomes and overall quality of life.
- European Market Expansion: BioMarin is also seeking approval from the European Medicines Agency to expand PALYNZIQ's indication to adolescents aged 12 and older in the European Union, further broadening its market reach.
- Market Reaction: Although BioMarin's stock rose by 1.01% to $61.73 during regular trading on Friday, it fell by 3.92% to $59.31 in after-hours trading, indicating mixed market reactions to the new approval.
See More
